AZN
ASTRAZENECA PLC
NYSE: AZN · Cambridge · Healthcare
$169.26+0.99 (+0.59%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$141.20 – $208.62
Avg Volume2.5M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$169.26+11.9%
Pipeline
Drug candidates sponsored by ASTRAZENECA · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | budesonide | Asthma | Completed | 2004-12past | 2 | |
| Phase 4 | Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2008-08past | 1 | |
| Phase 4 | Aclidinium bromide | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-06past | 1 | |
| Phase 3 | Galida | Diabetes Mellitus, Type 2 | Terminated | 2006-10past | 1 | |
| Phase 3 | Candesartan cilexetil | Hypertension | Completed | 2007-08past | 1 | |
| Phase 3 | Quetiapine XR | Anxiety Disorders | Completed | 2008-04past | 1 | |
| Phase 3 | Roflumilast | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2008-07past | 1 | |
| Phase 3 | NKTR-118 | Opioid-Induced Constipation (OIC)+3 more | Completed | 2012-09past | 2 | |
| Phase 3 | Aclidinium Bromide/Formoterol Fumarate | Chronic Obstructive Pulmonary Disease (COPD)+1 more | Completed | 2013-02past | 2 | |
| Phase 3 | fostamatinib | Rheumatoid Arthritis | Completed | 2013-02past | 1 | |
| Phase 3 | Dapagliflozin | Chronic Kidney Disease+1 more | Completed | 2020-06-12past | 2 | |
| Phase 3 | Ticagrelor | Sickle Cell Disease | Terminated | 2020-08-13past | 1 | |
| Phase 3 | Brilinta | Sickle Cell Disease | Withdrawn | 2022-10-10past | 1 | |
| Phase 3 | Benralizumab | Asthma+1 more | Active, not recruiting | 2023-08-10past | 2 | |
| Phase 3 | Trastuzumab Deruxtecan | Breast Neoplasms+2 more | Active, not recruiting | 2025-03-12past | 1 | |
| Phase 3 | Durvalumab (MEDI4736) | Non-muscle-invasive Bladder Cancer | Active, not recruiting | 2025-04-03past | 1 | |
| Phase 3 | capivasertib | Prostate Cancer | Active, not recruiting | 2026-03-04past | 1 | |
| Phase 3 | Unnamed | Asthma | Recruiting | 2027-10-13 | 1 | |
| Phase 3 | Volrustomig | Locally Advanced Cervical Cancer | Recruiting | 2027-11-26 | 1 | |
| Phase 3 | Rosuvastatin | Hypercholesterolemia+1 more | Completed | — | 1 | |
| Phase 3 | Quetiapine fumarate | Schizophrenia+1 more | Completed | — | 2 | |
| Phase 3 | Ropivacaine | Anesthesia,Spinal | Completed | — | 1 | |
| Phase 3 | Budesonide/formoterol Turbuhaler | Asthma | Completed | — | 1 | |
| Phase 3 | metoprolol succinate | Hypertension | Completed | — | 1 | |
| Phase 2 | Saxagliptin | Type 2 Diabetes Mellitus | Completed | 2004-05past | 1 | |
| Phase 2 | AZD3355 | Gastroesophageal Reflux Disease (GERD) | Completed | 2007-06past | 1 | |
| Phase 2 | AZD6244 | Non-small Cell Lung Cancer | Completed | 2007-07past | 1 | |
| Phase 2 | AZD2281 | Ovarian Carcinoma+1 more | Completed | 2010-03-26past | 1 | |
| Phase 2 | lesogaberan (AZD3355) | Gastroesophageal Reflux Disease+2 more | Completed | 2010-07past | 1 | |
| Phase 2 | AZD1386 | Sensitivity in Esophagus | Completed | 2011-01past | 1 | |
| Phase 2 | AZD2423 | Chronic Obstructive Pulmonary Disease+1 more | Completed | 2011-03past | 1 | |
| Phase 2 | Open-label AZD2014 | Squamous Non Small Cell Lung Cancer | Terminated | 2016-12-29past | 1 | |
| Phase 2 | AZD4547 | Gastro-oesophageal Junction Cancer+2 more | Active, not recruiting | 2020-03-18past | 2 | |
| Phase 2 | Acalabrutinib | COVID-19 | Completed | 2020-11-17past | 2 | |
| Phase 2 | AZD9977 | Heart Failure+1 more | Completed | 2023-09-22past | 1 | |
| Phase 2 | Ceralasertib | Melanoma | Active, not recruiting | 2024-04-12past | 1 | |
| Phase 2 | AZD5462 | Chronic Heart Failure | Completed | 2026-02-10past | 1 | |
| Phase 1 | AZD5851 | Hepatocellular Carcinoma | Active, not recruiting | 2027-12-13 | 1 | |
| Phase 1 | AZD9793 Intravenous (IV) monotherapy | Hepatocellular Carcinoma | Recruiting | 2028-02-25 | 1 | |
| Phase 1 | AZD7325 | Healthy Volunteer | Completed | 2008-09past | 1 | |
| Phase 1 | ABT-143 | Adverse Events+1 more | Completed | 2008-09past | 1 | |
| Phase 1 | AZD1940 | Low Back Pain | Completed | 2008-11past | 1 | |
| Phase 1 | metformin (Diabex) | Type 2 Diabetes Mellitus | Completed | 2010-04past | 1 | |
| Phase 1 | AZD1446 | Cognition | Completed | 2010-04past | 1 | |
| Phase 1 | AZD1656 | Healthy+2 more | Completed | 2010-05past | 3 | |
| Phase 1 | MEDI-578 | Osteoarthritis+1 more | Terminated | 2010-09past | 1 | |
| Phase 1 | AZD5069 | Healthy | Completed | 2011-02past | 1 | |
| Phase 1 | AZD1981 | Drug Interaction | Completed | 2011-04past | 1 | |
| Phase 1 | warfarin | Rheumatoid Arthritis+1 more | Completed | 2011-05past | 1 | |
| Phase 1 | AZD5213 | Brain Distribution of [11C]AZ12807110 and AZD5213 | Completed | 2011-06past | 1 | |
| Phase 1 | AZD7594 | Safety+2 more | Completed | 2013-06past | 1 | |
| Phase 1 | Saxagliptin/Metformin | Diabetes | Completed | 2013-07past | 1 | |
| Phase 1 | Rifampicin | Solid Tumours | Completed | 2014-05past | 1 | |
| Phase 1 | AZD9977, oral suspension | Safety+3 more | Completed | 2015-11past | 1 | |
| Phase 1 | AZD0284 | Plaque Psoriasis Vulgaris | Completed | 2017-05-30past | 1 | |
| Phase 1 | Epanova | Healthy Subjects | Completed | 2018-06-27past | 1 | |
| Phase 1 | AZD9150, Durvalumab | Advanced Solid Malignancies | Completed | 2019-04-12past | 1 | |
| Phase 1 | Zibotentan | Hepatic Impairment+2 more | Completed | 2023-01-10past | 2 | |
| Phase 1 | [14C]AZD4144 Solution for Infusion | Healthy Participants | Completed | 2026-05-26past | 1 | |
| Phase 1 | Saruparib (AZD5305) | Locally Advanced or Metastatic Solid Tumor | Recruiting | 2026-10-02 | 1 | |
| Phase 1 | 14C-AZD1236 | Healthy | Terminated | — | 1 | |
| Phase 1 | AZD4877 | Lymphoma | Terminated | — | 1 | |
| Phase 1 | AZD3199 Turbuhaler® | Healthy | Completed | — | 1 | |
| N/A | Unnamed | Prostate Cancer | Completed | 2007-10past | 1 | |
| N/A | Unnamed | Asthma | Completed | 2008-03past | 1 | |
| N/A | Unnamed | Bronchial Asthma | Completed | 2010-04past | 1 | |
| N/A | Unnamed | Breast Cancer | Completed | 2011-05past | 1 | |
| N/A | Unnamed | Breast Cancer | Terminated | 2011-06past | 1 | |
| N/A | Unnamed | Breast Cancer | Completed | 2011-11past | 1 | |
| N/A | Unnamed | Osteoarthritis of the Knee | Completed | 2012-06past | 1 | |
| N/A | Unnamed | Asthma | Completed | 2012-11past | 1 | |
| N/A | Unnamed | Type II Diabetes Mellitus | Completed | 2013-02past | 1 | |
| N/A | Unnamed | Non-Small Cell Lung Cancer | Completed | 2014-01past | 1 | |
| N/A | Unnamed | Dyslipidaemia | Completed | 2015-11past | 1 | |
| N/A | Unnamed | Acute Coronary Syndromes | Completed | 2017-04-05past | 1 | |
| N/A | Forxiga | Type 2 Diabetes Mellitus | Completed | 2017-12-31past | 1 | |
| N/A | Unnamed | Asthma | Completed | 2019-06-26past | 1 | |
| N/A | Unnamed | Type 2 Diabetes | Completed | 2019-11-29past | 1 | |
| N/A | Unnamed | Irritable Bowel Syndrome-IBS | Completed | 2023-02-03past | 1 | |
| N/A | Unnamed | COVID-19 | Completed | 2023-05-18past | 1 | |
| N/A | Unnamed | Covid-19 | Completed | 2023-07-11past | 1 | |
| N/A | Evusheld | SARS-CoV-2, COVID-19 | Completed | 2023-09-01past | 1 | |
| N/A | Unnamed | Heart Failure+1 more | Completed | 2024-05-20past | 1 | |
| N/A | Unnamed | Papillary Renal Cell Carcinoma | Recruiting | 2026-07-14past | 1 | |
| N/A | Unnamed | Neurofibromatosis Type 1 | Recruiting | 2026-09-30 | 1 | |
| N/A | Unnamed | Asthma, Bronchial | Recruiting | 2027-12-31 | 1 | |
| N/A | esomeprazole | GERD+1 more | Completed | — | 1 | |
| N/A | Unnamed | Breast Cancer | Completed | — | 1 | |
| N/A | Unnamed | Hypertension | Completed | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for AZN. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.